×
About 870 results

ALLMedicine™ Primary CNS Lymphoma Center

Research & Reviews  283 results

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02203526

Jul 1st, 2022 - Background: Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included hi...

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
https://clinicaltrials.gov/ct2/show/NCT03964090

Jul 1st, 2022 - Background: Aggressive B-cell lymphomas with secondary involvement of the CNS (sCNSL) have a grave prognosis No standard of care exists for sCNSL; treatment approaches include combination chemotherapy regimens effective in primary CNS lymphoma (PC...

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
https://clinicaltrials.gov/ct2/show/NCT05389423

Jul 1st, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: a ...
https://doi.org/10.1182/bloodadvances.2022007011
Blood Advances; Lesueur P, Damaj G et. al.

Jul 1st, 2022 - The optimal consolidation strategy for PCNSL remains controversial. Preventing radio-induced neurotoxicity of consolidation treatment through reduced-dose whole-brain irradiation (rdWBRT) at a dose of 23.4 Gy seems to be an interesting alternative...

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04609046

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with high dose-methotrexate (HD-MTX) and rituximab, with or without nivolumab, as induction treatment of primary CNS lymphoma. II. Determin...

see more →

Clinicaltrials.gov  47 results

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02203526

Jul 1st, 2022 - Background: Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included hi...

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
https://clinicaltrials.gov/ct2/show/NCT03964090

Jul 1st, 2022 - Background: Aggressive B-cell lymphomas with secondary involvement of the CNS (sCNSL) have a grave prognosis No standard of care exists for sCNSL; treatment approaches include combination chemotherapy regimens effective in primary CNS lymphoma (PC...

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
https://clinicaltrials.gov/ct2/show/NCT05389423

Jul 1st, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04609046

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with high dose-methotrexate (HD-MTX) and rituximab, with or without nivolumab, as induction treatment of primary CNS lymphoma. II. Determin...

Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04443829

Jun 14th, 2022 - The CAROUSEL Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with relapsed/refractory Primary CNS Lymphoma. The ATIMP for this study i...

see more →

News  18 results

CAR T-cell Therapy Demonstrates Efficacy Without Increased Risk of CRS or ICANS in CNS-Involved LBCL
https://www.onclive.com/view/car-t-cell-therapy-demonstrates-efficacy-without-increased-risk-of-crs-or-icans-in-cns-involved-lbcl

Apr 25th, 2022 - The CAR T-cell therapies axicabtagene ciloleucel (axi-cel; Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (liso-cel; Breyanzi) evoked responses without increased risk of cytokine release syndrome (CRS) or immune effector cell–...

Temporalis Muscle Thickness Predicts CNS Lymphoma Survival
https://www.medscape.com/viewarticle/964469

Dec 9th, 2021 - Key Takeaway Sarcopenia measured by temporalis muscle thickness (TMT) robustly and independently predicts early relapse and short survival in primary central nervous system (CNS) lymphoma. Very thin TMT is a better predictor of mortality than the ...

FDA Grants Orphan Drug Designation to CFT7455 for Multiple Myeloma
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-cft7455-for-multiple-myeloma

Aug 17th, 2021 - The FDA has granted an orphan drug designation to CFT7455, a MonoDAC degrader targeting IKZF1/3, for use as a potential therapeutic option in patients with multiple myeloma, according to an announcement from C4 Therapeutics, Inc.1 We are pleased ...

Thiotepa-Based Conditioning Promising for Primary CNS Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/92452

May 6th, 2021 - Two commonly used thiotepa-based conditioning regimens were associated with favorable outcomes among patients with primary central nervous system lymphoma (PCNSL) undergoing autologous hematopoietic cell transplant (AHCT), according to a retrospec...

Rituximab, Thiotepa, and Chemo Combo Improves Outcomes in Primary CNS Lymphoma
https://www.onclive.com/view/adding-rituximab-and-thiotepa-to-chemo-doublet-improves-outcomes-in-primary-cns-lymphoma

Dec 20th, 2020 - Andrés Ferreri, MD The MATRIX regimen, comprised of a methotrexate/cytarabine backbone plus thiotepa and rituximab, improved outcomes in patients with primary CNS lymphoma, according to results from the international randomized phase II ELSG #3...

see more →